Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5

FEBS Letters

Volumn 584, Issue 13, 2010, Pages 2867-2871

  Frese Schaper, Manuela ^a   Schardt, Julian A ^b   Sakai, Toshiyuki ^c   Carboni, Giovanni L ^b   Schmid, Ralph A ^b   Frese, Steffen ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Death receptor 5; Lung cancer; Resistance to apoptosis; Tissue transglutaminase; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTRON; LUNG CANCER; PLASMID; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIZATION; UPREGULATION;

APOPTOSIS; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; INTRONS; ISOXAZOLES; LUNG NEOPLASMS; PROMOTER REGIONS, GENETIC; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSGLUTAMINASES; UP-REGULATION;

EID: 77953726947     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2010.04.072     Document Type: Article

References (21)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58:71-96.
2. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., Krammer P.H., Walczak H. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000, 12:599-609.
3. Walczak H., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999, 5:157-163.
4. Ashkenazi A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999, 104:155-162.
5. Chen J.S., Mehta K. Tissue transglutaminase: an enzyme with a split personality. Int. J. Biochem. Cell Biol. 1999, 31:817-836.
6. Lorand L., Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 2003, 4:140-156.
7. Verma A., Wang H., Manavathi B., Fok J.Y., Mann A.P., Kumar R., Mehta K. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res. 2006, 66:10525-10533.
8. Yuan L., Siegel M., Choi K., Khosla C., Miller C.R., Jackson E.N., Piwnica-Worms D., Rich K.M. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 2007, 26:2563-2573.
9. Frese S., Frese-Schaper M., Andres A.C., Miescher D., Zumkehr B., Schmid R.A. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res. 2006, 66:5867-5874.
10. Frese-Schaper M., Zbaeren J., Gugger M., Monestier M., Frese S. Reversal of established lupus nephritis and prolonged survival of New Zealand Black×New Zealand White Mice treated with the topoisomerase I inhibitor irinotecan. J. Immunol. 2010, 184:2175-2182.
11. Wang S., El-Deiry W.S. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc. Natl. Acad. Sci. USA 2003, 100:15095-15100.
12. Yoshida T., Sakai T. Promoter of TRAIL-R2 gene. Vitam. Horm. 2004, 67:35-49.
13. Shetty S., Graham B.A., Brown J.G., Hu X., Vegh-Yarema N., Harding G., Paul J.T., Gibson S.B. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol. Cell. Biol. 2005, 25:5404-5416.
14. Yoshida T., Shiraishi T., Nakata S., Horinaka M., Wakada M., Mizutani Y., Miki T., Sakai T. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 2005, 65:5662-5667.
15. Hausch F., Halttunen T., Maki M., Khosla C. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase. Chem. Biol. 2003, 10:225-231.
16. Yuan L., Choi K., Khosla C., Zheng X., Higashikubo R., Chicoine M.R., Rich K.M. Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol. Cancer Ther. 2005, 4:1293-1302.
17. Cao L., Petrusca D.N., Satpathy M., Nakshatri H., Petrache I., Matei D. Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 2008, 29:1893-1900.
18. Tatsukawa H., et al. Role of transglutaminase 2 in liver injury via cross-linking and silencing of transcription factor Sp1. Gastroenterology 2009, 136:1783-1795. (e10).
19. Chen J.J., Chou C.W., Chang Y.F., Chen C.C. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. J. Immunol. 2008, 180:8030-8039.
20. Rath P.C., Mukhopadhyay T. P53 gene expression and 2-methoxyestradiol treatment differentially induce nuclear factor kappa B activation in human lung cancer cells with different p53 phenotypes. DNA Cell Biol. 2009.
21. Campling B.G., El-Deiry W.S. Clinical implication of p53 mutation in lung cancer. Mol. Biotechnol. 2003, 24:141-156.